Placebo News and Research

RSS

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Heart failure patients with iron deficiency can experience significant and sustainable improvements in functional capacity and quality of life as well as reduced risk of hospital admission for worsening heart failure by receiving just one to two intravenous doses of an iron supplement, according to the results of a study presented today at ESC Congress 2014.

30 Aug 2014

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014.

30 Aug 2014

Plant-based medication after cardiac surgery shows mixed results in reducing complications

Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA.

30 Aug 2014

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s.

29 Aug 2014

New treatment fights respiratory syncytial virus

The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

29 Aug 2014

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.

28 Aug 2014

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy.

28 Aug 2014

Risk-based treatment approach should be considered for patients with hypertension

Blood pressure-lowering treatment should target patients at greatest cardiovascular risk and not just those with the highest baseline levels, suggest findings of a meta-analysis.

28 Aug 2014

Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide.

28 Aug 2014

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.

28 Aug 2014

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology.

28 Aug 2014

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF).

28 Aug 2014

EPO administered to preterm infants linked with reduced risk of brain injury

High-dose erythropoietin (EPO; a hormone) administered within 42 hours of birth to preterm infants was associated with a reduced risk of brain injury, as indicated by magnetic resonance imaging, according to a study in the August 27 issue of JAMA.

27 Aug 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting.

25 Aug 2014

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis.

22 Aug 2014

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite.

21 Aug 2014

NeuroDerm signs definitive investment agreements for $16 million financing round

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group.

21 Aug 2014

Investigational drug focuses on slowing Alzheimer's disease progression

Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug that proposes to do just that.

21 Aug 2014

Studies support clinical use of antidepressants for treatment of postoperative pain

Antidepressants are known to provide effective pain relief for various chronic pain conditions; however, the jury is still out on their use in treating the millions of patients who suffer from acute or chronic pain following surgery.

20 Aug 2014

Perampanel does not offer added benefit for patients with Epilepsy

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures).

20 Aug 2014

Placebo News and Research

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

Plant-based medication after cardiac surgery shows mixed results in reducing complications

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

New treatment fights respiratory syncytial virus

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Vaccine boosts advanced NSCLC patient survival

Risk-based treatment approach should be considered for patients with hypertension

Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

New MS treatment found safe, tolerable in phase I clinical trials

Experimental drug shows promise as viable treatment for anemia of inflammation

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

EPO administered to preterm infants linked with reduced risk of brain injury

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

NeuroDerm signs definitive investment agreements for $16 million financing round

Investigational drug focuses on slowing Alzheimer's disease progression

Studies support clinical use of antidepressants for treatment of postoperative pain

Perampanel does not offer added benefit for patients with Epilepsy

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News